title: Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET.
abstract: The objective of this study is to reevaluate the clinical significance of 1-11C-acetate (ACE) positron emission tomography (PET) in patients with brain glioma, in comparison with 18F-fluorodeoxyglucose (FDG) PET.
  
  
  METHODS
  Ten patients with histologically proven glioma were included in this study. They underwent PET examination with both FDG and ACE on separate days. For ACE PET, 20-min data acquisition was performed just after the administration of 740 MBq of ACE; 10-20-min data were used for the analysis. FDG PET data acquisition for 10 min started 60 min postinjection of 370 MBq of FDG, approximately. Both reconstructed images were converted to standardized uptake value (SUV) images for patient body weight and injected dose. Regions of interest were placed on the tumor and the contralateral cerebral cortex, and SUV and tumor-to-cortex ratio (T/C) were calculated; these values were compared between high- and low-grade gliomas.
  
  
  RESULTS
  SUV and T/C of ACE PET showed significant difference (SUV: 2.63+/-0.46 vs. 1.85+/-0.56, P=.03; T/C: 2.36+/-0.63 vs. 1.14+/-0.36, P=.02). In contrast, FDG PET revealed no significant difference in SUV or T/C between high- and low-grade gliomas (SUV: 7.13+/-4.31 vs. 4.71+/-1.27, P=.31; T/C: 0.98+/-0.55 vs. 0.62+/-0.09, P=.22).
  
  
  CONCLUSIONS
  This preliminary study revealed that ACE PET is a promising tracer for the grading of brain glioma.
authors.affiliation: Department of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan. tsucchy@u-fukui.ac.jp
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Tsuchida
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Takeuchi
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Okazawa
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tsujikawa
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Fujibayashi
mesh_terms: D000085:Acetates / Q000493:pharmacokinetics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001254:Astrocytoma / Q000000981:diagnostic imaging* / Q000473:pathology*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology*; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics*; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000473:pathology; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005909:Glioblastoma / Q000000981:diagnostic imaging* / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics
chemical_list: D000085:Acetates; D002250:Carbon Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18